Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 9,447	$ 25,178
General and administrative	17,695	26,012
Goodwill impairment charge	0	825
Intangible asset impairment charge	5,900	0
Fair value adjustment for contingent consideration	1,578	0
Total operating expenses	34,620	52,015
Loss from operations	(34,620)	(52,015)
Fair value adjustment for long-term debt	(338)	0
Interest income	3,478	1,068
Other expense, net	(102)	(997)
Net loss before income tax benefit	(31,582)	(51,944)
Income tax benefit	197	284
Net loss	(31,385)	(51,660)
Other comprehensive income (loss):
Foreign currency translation adjustments	2,789	248
Unrealized gain (loss) on available-for-sale securities	547	(458)
Total comprehensive loss	$ (28,049)	$ (51,870)
Net loss per share - basic	$ (0.84)	$ (1.54)
Net loss per share - diluted	$ (0.84)	$ (1.54)
Weighted average shares of common stock outstanding - basic	37,237,149	33,496,534
Weighted average shares of common stock outstanding - diluted	37,237,149	33,496,534